SCHEMBL1489540

SCHEMBL1489540

NC(=O)C(=O)c1ccc(O)c(O)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.58
CA1 P00915 4/20 0.58
CA2 P00918 4/20 0.58
CA7 P43166 4/20 0.58
CA9 Q16790 4/20 0.58
CA14 Q9ULX7 4/20 0.58
KDM4E B2RXH2 3/20 0.58
MAPT P10636 3/20 0.58
GAA P10253 2/20 0.58
POLB P06746 2/20 0.58
L3MBTL1 Q9Y468 2/20 0.58
CA4 P22748 1/20 0.58
CA6 P23280 1/20 0.58
PTGS2 P35354 1/20 0.58
HDAC6 Q9UBN7 1/20 0.52
RECQL P46063 2/20 0.50
DBH P09172 1/20 0.50
XDH P47989 1/20 0.50
TOP1 P11387 3/20 0.48
MEN1 O00255 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28842093 1.00 CA12 (0.58) CA12CA1CA2CA7CA9
Catechol SCHEMBL28195172 0.94 KDM4E (0.52) CA12CA1CA2CA7CA9
SCHEMBL1599733 0.85 CA12 (0.68) CA12CA1CA2CA7CA9
SCHEMBL4444024 0.82 MEN1 (0.42) CA12CA1CA2CA7CA9
Protocatechuamide SCHEMBL1128716 0.81 LCK (0.65) CA12CA1CA2CA7CA9
Protocatechuamide SCHEMBL28613093 0.79 LCK (0.63) CA12CA1CA2CA7CA9
SCHEMBL29712028 0.79 CA12 (0.67) CA12CA1CA2CA7CA9
SCHEMBL28765726 0.79 CA12 (0.67) CA12CA1CA2CA7CA9
SCHEMBL23270110 0.78 CA12 (0.54) CA12CA1CA2CA7CA9
SCHEMBL15680192 0.77 CA12 (0.58) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 451 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120082353-A Thioether bond bridged carbon dot-dopamine quinone composite probe and application thereof in glioblastoma cell fluorescence imaging 西南医科大学 2025-06-03 CN claimed
CN-115219428-B Interference-free SERS probe and preparation method and application thereof 新疆师范大学 2025-05-13 CN claimed
CN-118639409-A Composite filter material CO ablation net loaded with powdery ablative agent and preparation method thereof 辽宁工程技术大学鄂尔多斯研究院 2024-09-13 CN claimed
CN-116219763-B Natural durable antibacterial super-hydrophobic cellulose fabric and preparation method thereof 东华大学 2024-08-23 CN claimed
WO-2024159712-A1 NATURAL AND DURABLE ANTIMICROBIAL SUPERHYDROPHOBIC CELLULOSE FABRIC AND PREPARATION METHOD THEREFOR 东华大学 2024-08-08 WO claimed
CN-115404696-B Dopamine quinone fiber and preparation method, application and application method thereof 天津大学 2023-12-12 CN claimed
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 CN claimed
CN-116219763-A Natural durable antibacterial super-hydrophobic cellulose fabric and preparation method thereof 东华大学 2023-06-06 CN claimed
CN-115404696-A Dopamine quinone fiber, and preparation method, application and application method thereof 天津大学 2022-11-29 CN claimed
CN-112179262-B Functional graphene-based flexible strain sensor and preparation method and application thereof 中国科学院理化技术研究所 2022-11-22 CN claimed
US-20130266557-A1 METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) BERG THERAPEUTICS, LLC 2013-10-10 US claimed
CN-103196967-A Dopamine polymer/noble metal nanoparticle electrochemical sensor as well as preparation method and application thereof UNIV SHANGHAI 2013-07-10 CN claimed
CN-102277728-B Method for preparing conductive ultrahigh molecular weight polyethylene fiber NINGBO INST MAT TECH & ENG CAS 2012-12-26 CN claimed
EP-2470169-A2 METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) Cytotech Labs, LLC (US) 2012-07-04 EP claimed
CN-102277728-A Method for preparing conductive ultrahigh molecular weight polyethylene fiber NINGBO INST MAT TECH & ENG CAS 2011-12-14 CN claimed
WO-2011031503-A2 METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) CYTOTECH LABS, LLC (US) 2011-03-17 WO claimed
US-20110064747-A1 METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) BERG PHARMA LLC 2011-03-17 US claimed
US-20080300204-A1 Alpha-Synuclein Antibodies and Methods Related Thereto UNIVERSITY OF ROCHESTER 2008-12-04 US claimed
EP-1915177-A2 ALPHA-SYNUCLEIN ANTIBODIES AND METHODS RELATED THERETO University of Rochester (US) 2008-04-30 EP claimed
WO-2007011907-A2 ALPHA-SYNUCLEIN ANTIBODIES AND METHODS RELATED THERETO UNIVERSITY OF ROCHESTER (US) 2007-01-25 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130266557-A1 METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) NDUFB10, SDHB, SDHA CA12 3539/4885CA1 4439/4885CA2 4361/4885
US-20110064747-A1 METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) NDUFB10, SDHB, SDHA CA12 3539/4885CA1 4439/4885CA2 4361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.